UK-CAB 12 – Children and HIV – UK treatment guidelines

28 January 2005

Programme

Reading Material

Programme

08:45–09:00 Registration and coffee/tea
09:00–09:15 Introductions, outline for the day
09:30–11:00 Approaches to Paediatric HIV Care
11:00–11:30 Break
11:30–13:00 Introduction to guidelines.1

1) Synopsis
2) Introduction
3) When to start treatment
4) What to start with
5) Issues concerning antiretroviral use

13:00–14:00
Lunch
14:00–15:30
Introduction to guidelines.2

6) Changing or stopping therapy in the absence of virological failure
7) Changing and stopping therapy for virological failure
8) New therapies
9) References
10) Conflict of interest
11) List of Tables

15:30–15:45
Break
15:45–16:30 Conclusions for community input into guidelinesProgramme for 2005 and next meeting
16:30 Meeting close

Link to top of page

PowerPoint Slides form the meeting
Paediatric_UKCAB-jan05.ppt [552k]
BHIVA_guides_UKCAB-jan05.ppt [84k]
UK_CAB-Pipeline_drugs.ppt [620k]

Training for this meeting

Training for this meeting will cover two subjects:

i) children and HIV – with a focus on treatment and treatment related issues for HIV-positive children – speaker to be confirmed.

ii) UK Treatment Guidelines – the BHIVA guidelines are being updated, so we can run an in-depth training session based on the existing guidelines and the changes that we expect in the next revision.

This session will therefore cover the controversial aspects around the main questions: when to start? which drugs to use? when to change treatment? access to viral load and resistance tests etc etc.

Five CAB members are already taking a lead in providing community input into the guidelines updates, and they can each present on their specialised area.
Link to top of page

Reading Material

The following links are to articles relating to different issues that affect children and HIV.

The following articles are either from recent issues of HTB, or sections form a report form a meeting on paediatric care that i-Base organised in 2001.

Higher nelfinavir concentrations improve response in children
http://www.i-base.info/pub/htb/v5/htb5-4/Higher.html

PK of once daily lopinavir/r in children
http://www.i-base.info/pub/htb/v5/htb5-4/PK.html

New tool for assessing risks of disease progression and death based on age, CD4 percentage and viral load in HIV-infected children
http://www.i-base.info/pub/htb/v4/htb4-10/New.html

From Paediatric HIV Care:
http://www.i-base.info/pub/paed/index.html

Helping children take HAART: taste and formulations:
http://www.i-base.info/pub/paed/help.html

Simplifying adherence: use of PEG-tubes:
http://www.i-base.info/pub/paed/gtubes.html

Additional reading
http://www.bhiva.org/chiva/index.html

A recently updated set of paediatric guidelines from New York are also much more recent than anything available in the UK and are a good reference source:
http://www.hivguidelines.org/clinical-guidelines/infants-children/pediatric-antiretroviral-therapy/

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.
Link to top of page

Edit
Published: January 28, 2005
Last edited: August 15, 2013